

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Pellet and Sanchez-Martinez

**Patent No.** 6,126,944

**Issued:** October 3, 2000

**FILED VIA EFS**

**Application No.** 08/480,850

**Filed:** June 7, 1995

**Confirmation No.** 9684

**For:** BACULOVIRUS EXPRESSION VECTORS  
AND RECOMBINANT ANTIGENS FOR  
DETECTING TYPE-SPECIFIC  
ANTIBODIES TO HERPES SIMPLEX  
VIRUS

**Examiner:** Louise N. Leary

**Art Unit:** 1623

**Attorney Reference No.** 6395-87124-02

SUBMITTED VIA THE ELECTRONIC FILING SYSTEM (EFS)  
COMMISSIONER FOR PATENTS

**DECLARATION OF SHARON SHROPSHIRE**

1. I, Sharon Shropshire, am the Technology Transfer Assistant for the Centers for Disease Control and Prevention (CDC) Technology Transfer Office (TTO) in Atlanta, Georgia, which is an agency within the Assignee of the above-referenced U.S. Patent No. 6,126,944, which is assigned to The United States of America as Represented by the Secretary of the Department of Health and Human Services (hereinafter "the Government").

2. In 2007 and 2008, the procedure at the CDC was that when patent correspondence such as a Notice of Expiration was received, it was first date stamped by me. I would then forward the patent correspondence to Ms. Veronica Brown to enter any relevant due dates into the electronic database (Inteum). Ms. Cynthia Sherwood reviewed any docket dates after Ms. Brown entered them into the electronic database. Following this review, the patent correspondence was then provided to the appropriate licensing professional.

3. I was working on November 28, 2008, the day after Thanksgiving. I believe I date stamped the Notice of Expiration for the above-referenced patent. However, a letter

accompanied this notice which was addressed to Mr. Paco Candal. Thus, I put the Notice of Expiration into his mailbox, rather than forward the notice to Ms. Brown pursuant to the regular procedure.

4. All statements made herein and of my own knowledge are true and all statements made on information are believed to be true; and further, these statements were made with the knowledge that willful false statements and like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that any such willful false statements made may jeopardize the validity of the application or any patent issuing thereon.

9-16-2011  
Date

Sharon Shropshire  
Sharon Shropshire